GSK Reports Results of Zejula (niraparib) in P-III PRIMA Study as 1L Maintenance Therapy for Ovarian Cancer

Shots:

• The P-III PRIMA study involves assessing of Zejula (200 mg, qd) vs PBO as 1L maintenance therapy in patients in a ratio (2:1) with stage III or IV ovarian cancer following platinum-based chemotherapy
• The P-III PRIMA study resulted in meeting its 1EPs i.e, improvement in PFS in women regardless of their biomarker status, safe & tolerable
• Zejula is a PARP inhibitor, being evaluated in P-III studies in multiple clinical studies as monothx. or in combination with other drugs for breast cancer and ovarian cancer. Janssen has WW rights to develop and commercialize niraparib for prostate cancer (Ex-Japan)

Click here to read full press release/ article | Ref: GSK | Image: Glassdoor